Bleeding on HRT: When It Is Expected and When It Is Investigated
Bleeding is the symptom on hormone therapy that has rules. Not guidelines, not judgement calls — rules, of the kind that say this gets an ultrasound, no exceptions. They exist because the one serious thing hormone therapy can do to a uterus announces itself as bleeding, and because the far more common harmless bleeding looks the same from the outside.
This page sets out those rules as they apply to a woman on estradiol with micronized progesterone. It is deliberately short on reassurance and long on what to report.
Why progesterone is in this story
Estrogen makes the lining of the uterus grow. Progesterone stops it growing, and — depending on how it is taken — either sheds it on a schedule or holds it thin. That is the whole reason a woman with a uterus takes progesterone alongside estrogen: without it, the lining thickens year on year, and thickened lining is where endometrial cancer begins. The FDA retained exactly one boxed warning on estrogen products in November 2025, and it was this one.
So bleeding on hormone therapy is, at bottom, a question about whether the progesterone is doing its job. Sometimes the answer is "yes, and this is the expected pattern." Sometimes the answer is "we need to look."
What is expected
In the first months. Irregular spotting or light bleeding after starting continuous combined therapy — estrogen and progesterone every day — is common, and in most women settles within the first six months as the lining adapts to a steady state. This is the one situation in which bleeding is usually watched rather than investigated, provided it is light, provided it is settling, and provided nothing else on this page applies.
On a cyclic regimen. A woman still in perimenopause, taking progesterone for part of each month, is expected to bleed — a withdrawal bleed at a predictable point. That is the regimen working. Bleeding at other times in the cycle is not expected.
After a missed progesterone. A forgotten capsule can produce a bleed within days. It is worth reporting, and it is worth not repeating.
What is always investigated
Bleeding that continues beyond six months on continuous combined therapy, or that starts again after a bleed-free interval.
Heavy bleeding at any point — soaking through protection, clots, bleeding that affects daily life.
Any bleeding in a woman who was postmenopausal before starting and who has been on continuous therapy long enough for the early phase to have passed. The general rule of gynecology applies with full force: bleeding after menopause is investigated until a cause is found.
Bleeding in a woman on estrogen who is not taking progesterone — because of a hysterectomy she believed removed the need, or because she stopped it, or because she is using a progesterone cream that does not protect the lining. This is the highest-priority case on the page.
Investigation usually means a transvaginal ultrasound to measure the lining, sometimes an endometrial biopsy, occasionally a hysteroscopy. It is a gynecologist's work, and the referral is prompt. Most of the time the result is benign — a polyp, a thick-but-normal lining, a regimen that needs adjusting. The point of looking is the minority of times it is not.
What you do not do
You do not stop the progesterone to "see if the bleeding stops." Stopping progesterone in a woman on estrogen removes the protection while leaving the stimulus, and it converts an ambiguous symptom into an unprotected uterus.
You do not double the progesterone, skip the estrogen, or change the schedule on your own initiative. Every one of those is a clinical adjustment with consequences, and every one of them muddies the picture your clinician needs to read. We say this not because self-adjustment is disobedient but because it is the single most common way a manageable bleeding pattern becomes a confusing one.
You report it. Same week, not next review. Our assessment questions ask about bleeding at every check-in for exactly this reason, and a message between check-ins is welcome.
Frequently asked questions
Light, irregular bleeding in the first six months of continuous combined therapy is common and usually settles. Heavy bleeding, or bleeding that persists beyond six months, is investigated.
Report it this week. After the early adjustment phase, bleeding in a postmenopausal woman on continuous therapy is evaluated — usually with an ultrasound — until a cause is found.
No. That removes the uterine protection while the estrogen continues. Report the bleeding; do not change the regimen yourself.
Not reliably. Over-the-counter and compounded creams do not achieve the lining protection that oral micronized progesterone does. See the progesterone cream page.
Usually a transvaginal ultrasound; sometimes an endometrial biopsy; occasionally a hysteroscopy. Most results are benign. The investigation is done because of the minority that are not.
Rarely — a retained cervix or residual endometriosis can bleed. Any bleeding after hysterectomy is reported and examined.
Where this fits in your plan
The Progesterone Capsule page explains why progesterone is not optional; the women's HRT page covers what ongoing care looks like, of which bleeding surveillance is part.
We measure first. Then we act.
References
- ACOG Committee Opinion No. 734: The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Women With Postmenopausal Bleeding. Obstetrics & Gynecology 2018;131:e124–e129.
- The Menopause Society. The 2022 Hormone Therapy Position Statement. Menopause 2022;29:767–794 — endometrial protection and unscheduled bleeding.
- British Menopause Society. Management of unscheduled bleeding on HRT. Tool for clinicians, 2024.
- FDA. HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. November 10 2025 — retention of the endometrial cancer boxed warning.
- Sjögren LL, Mørch LS, Løkkegaard E. Hormone replacement therapy and the risk of endometrial cancer: a systematic review. Maturitas 2016;91:25–35.
- Back toProgesterone Capsule
- Progesterone cream: what it can and can't doA topical progesterone option, for use where endometrial protection is not the goal.Read
- Estradiol after hysterectomyNo uterus means no progesterone requirement — and a different risk picture. Whether your ovaries were removed changes the timing. What estrogen-alone therapy involves.Read
- Progesterone alone in perimenopauseIn the years before periods stop, the hormone that falls first is progesterone, not estrogen. Why progesterone-first is a legitimate plan, what it addresses, and what it does not.Read
How we write and review our content
ACT 2 Health provides clinician-led care. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. This content is educational and is not medical advice. Individual results vary.
Compounded medication. Prepared by a licensed compounding pharmacy under a prescription written for you. Compounded medications are not FDA-approved, are not reviewed by the FDA for safety or effectiveness, and are not equivalent to or interchangeable with any branded product. Prescribed only when a licensed provider determines it is medically appropriate.
Care is delivered via telemedicine by healthcare professionals licensed in the state where the patient is located. Services are available only in states where our providers are licensed.
Heavy bleeding, or any bleeding with pain, fever or faintness, needs prompt in-person care.